Publication Date: 25 Apr 2013
Citation: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7 17-34
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
PDF (700.86 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
My experience with Int J Tryptophan Research has been excellent. The editors and reviewers were most helpful and very "open" intellectually given we were proposing a novel and counter-intuitive hypothesis. The administrative staff have been patient, quick, helpful and friendly. I would and have recommended this group of journals to colleagues.